|   Fluoxymesterone structure | Common Name | Fluoxymesterone | ||
|---|---|---|---|---|
| CAS Number | 76-43-7 | Molecular Weight | 336.441 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 474.2±45.0 °C at 760 mmHg | |
| Molecular Formula | C20H29FO3 | Melting Point | 240 °C | |
| MSDS | N/A | Flash Point | 240.6±28.7 °C | |
| Symbol |       GHS02, GHS07, GHS08 | Signal Word | Danger | |
| Use of FluoxymesteroneFluoxymesterone is an Androgen. The mechanism of action of fluoxymesterone is as an Androgen Receptor Agonist. | 
| Name | Fluoxymesterone | 
|---|---|
| Synonym | More Synonyms | 
| Density | 1.2±0.1 g/cm3 | 
|---|---|
| Boiling Point | 474.2±45.0 °C at 760 mmHg | 
| Melting Point | 240 °C | 
| Molecular Formula | C20H29FO3 | 
| Molecular Weight | 336.441 | 
| Flash Point | 240.6±28.7 °C | 
| Exact Mass | 336.210083 | 
| PSA | 57.53000 | 
| LogP | 2.17 | 
| Vapour Pressure | 0.0±2.7 mmHg at 25°C | 
| Index of Refraction | 1.562 | 
| Water Solubility | NEGLIGIBLE | 
| 
 Synonym:(11beta,17beta)-9-Fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-on Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS 
 Risk Phrases: None Listed. Section 3 - HAZARDS IDENTIFICATION   EMERGENCY OVERVIEW
 The toxicological properties of this material have not been fully investigated. Potential Health Effects Eye: May cause eye irritation. Skin: May cause skin irritation. Ingestion: The toxicological properties of this substance have not been fully investigated. Inhalation: May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Chronic: Prolonged or repeated exposure may cause adverse reproductive effects. Section 4 - FIRST AID MEASURES Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. Skin: Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Ingestion: Get medical aid. Wash mouth out with water. Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Notes to Physician: Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or chemical foam. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions. Section 7 - HANDLING and STORAGE Handling: Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Storage: Store in a cool, dry place. Store in a tightly closed container. Hormones and antibiotics room. Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 76-43-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Solid Color: white Odor: Odorless pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: 240 deg C dec Autoignition Temperature: Not available. Flash Point: Not available. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Solubility in water: negligible Specific Gravity/Density: Molecular Formula: C20H29FO3 Molecular Weight: 336.45 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Stable. Conditions to Avoid: Incompatible materials. Incompatibilities with Other Materials: Strong oxidizing agents. Hazardous Decomposition Products: Carbon monoxide, carbon dioxide, hydrogen fluoride gas. Hazardous Polymerization: Will not occur. Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 76-43-7: BV8390000 LD50/LC50: Not available. Carcinogenicity: FLUOXYMESTERONE - Not listed by ACGIH, IARC, or NTP. Other: See actual entry in RTECS for complete information. Section 12 - ECOLOGICAL INFORMATION Section 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations. Section 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material. Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: Not available. Risk Phrases: Safety Phrases: S 24/25 Avoid contact with skin and eyes. WGK (Water Danger/Protection) CAS# 76-43-7: No information available. Canada CAS# 76-43-7 is listed on Canada's DSL List. CAS# 76-43-7 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 76-43-7 is not listed on the TSCA inventory. It is for research and development use only. SECTION 16 - ADDITIONAL INFORMATION N/A | 
| CHEMICAL IDENTIFICATION
 
 
 
 
 
 
 
 
 HEALTH HAZARD DATAACUTE TOXICITY DATA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MUTATION DATA
 
 
 | 
| Symbol |       GHS02, GHS07, GHS08 | 
|---|---|
| Signal Word | Danger | 
| Hazard Statements | H225-H315-H360FD | 
| Supplemental HS | May form explosive peroxides. | 
| Precautionary Statements | P201-P210-P280-P308 + P313-P370 + P378-P403 + P235 | 
| Hazard Codes | Xn: Harmful; | 
| Risk Phrases | R63 | 
| Safety Phrases | S22-S36-S24/25 | 
| RIDADR | UN2252 - class 3 - PG 2 - 1,2-Dimethoxyethane solution | 
| WGK Germany | 3 | 
| RTECS | BV8390000 | 
| HS Code | 2937290018 | 
| ~%   Fluoxymesterone CAS#:76-43-7 | 
| Literature: Journal of the American Chemical Society, , vol. 78, p. 500 US2793218 , ; | 
| ~%   Fluoxymesterone CAS#:76-43-7 | 
| Literature: Journal of the American Chemical Society, , vol. 78, p. 500 US2793218 , ; | 
| ~%   Fluoxymesterone CAS#:76-43-7 | 
| Literature: Journal of the American Chemical Society, , vol. 78, p. 500 | 
| Precursor 3 | |
|---|---|
| DownStream 1 | |
| HS Code | 2937290018 | 
|---|
| Rat liver lysosomal and mitochondrial activities are modified by anabolic-androgenic steroids. Med. Sci Sports Exerc. 31 , 243, (1999) The aim of this study was to examine the separate and combined effects of an 8-wk treatment with high doses of 17alpha-alkylated anabolic-androgenic steroids (AAS) and exercise training on selected ly... | |
| Biotransformation of 17-alkyl steroids in the equine: high-performance liquid chromatography-mass spectrometric and gas chromatography-mass spectrometric analysis of fluoxymesterone metabolites in urine samples. J. Chromatogr. B. Biomed. Sci. Appl. 704 , 119, (1997) In this study the equine metabolism of fluoxymesterone (9alpha-fluoro-11beta-17beta-dihydroxy-17alpha-meth ylandrost-4-ene-3-one) given orally has been investigated. The parent material was not detect... | |
| Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J. Clin. Oncol. 18(2) , 262-6, (2000) Although hormonal therapy represents standard therapy for metastatic hormone-sensitive disease, many patients receive initial chemotherapy because of the location, bulk, or aggressiveness of their dis... | 
| 11b,17b-Dihydroxy-9a-fluoro-17a-methyl-4-androsten-3-one | 
| (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one | 
| Testosterone, 9-fluoro-11β-hydroxy-17-methyl- | 
| 9a-Fluoro-11b-hydroxy-17a-methyltestosterone | 
| MFCD00010480 | 
| 9α-Fluoro-11β-hydroxy-17-methyltestosterone | 
| (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one | 
| Androst-4-en-3-one, 9-fluoro-11β,17β-dihydroxy-17-methyl- | 
| Halotestin | 
| EINECS 200-961-8 | 
| Androst-4-en-3-one, 9-fluoro-11,17-dihydroxy-17-methyl-, (11β,17β)- | 
| fluoxymesterone | 
| (8S,9R,10S,11S,13S,14S,17S)-9-Fluor-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-on | 
| (11β,17β)-9-Fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one | 
| (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-triméthyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tétradécahydro-3H-cyclopenta[a]phénanthrén-3-one |